Recombinant SARS-CoV-2 Fusion Protein Vaccine
V-01-I-Booster
Phase 1 mab completed
Quick answer
Recombinant SARS-CoV-2 Fusion Protein Vaccine for COVID19 is a Phase 1 program (mab) at Livzon Pharmaceutical Group with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Livzon Pharmaceutical Group
- Indication
- COVID19
- Phase
- Phase 1
- Modality
- mab
- Status
- completed